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Background: In human vaccine manufacturing some pathogens such as Modified Vaccinia Virus Ankara, measles,
mumps virus as well as influenza viruses are still produced on primary material derived from embryonated chicken
eggs. Processes depending on primary cell culture, however, are difficult to adapt to modern vaccine production.
Therefore, we derived previously a continuous suspension cell line, AGE1.CR.pIX, from muscovy duck and
established chemically-defined media for virus propagation.
Results: To better understand vaccine production processes, we developed a stoichiometric model of the central
metabolism of AGE1.CR.pIX cells and applied flux variability and metabolic flux analysis. Results were compared to
literature dealing with mammalian and insect cell culture metabolism focusing on the question whether cultured
avian cells differ in metabolism. Qualitatively, the observed flux distribution of this avian cell line was similar to
distributions found for mammalian cell lines (e.g. CHO, MDCK cells). In particular, glucose was catabolized
inefficiently and glycolysis and TCA cycle seem to be only weakly connected.
Conclusions: A distinguishing feature of the avian cell line is that glutaminolysis plays only a minor role in energy
generation and production of precursors, resulting in low extracellular ammonia concentrations. This metabolic flux
study is the first for a continuous avian cell line. It provides a basis for further metabolic analyses to exploit the
biotechnological potential of avian and vertebrate cell lines and to develop specific optimized cell culture
processes, e.g. vaccine production processes.
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GlutaminolysisBackground
Novel therapeutic options have been made possible with
production of animal cell culture-derived biopharmaceu-
ticals. An enormous amount of insight has been pub-
lished on production of recombinant proteins (including
antibodies) since the first products have been licensed
for application in humans 1986 and 1987. CHO cells are
the main substrate for recombinant proteins and there-
fore most metabolic studies describe these cells [1,2]. Re-
garding vaccine manufacturing, literature on properties
and metabolism of host cells during growth and virus* Correspondence: verena.lohr@probiogen.de
†Equal contributors
1Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr.
1, 39106 Magdeburg, Germany
2Current address: ProBioGen AG, Goethestr. 54, 13086 Berlin, Germany
Full list of author information is available at the end of the article
© 2014 Lohr et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.replication as well as process design and optimization is
less abundant and not as focused. One reason is that safety
considerations and execution of pre-clinical and clinical
trials are paramount for vaccines because this medication
usually is administered to healthy recipients. Another
reason is the multitude of process options and host cell
systems used for propagation of pathogens. For historic
reasons, primary cultures (today usually embryonated
chicken eggs or chicken embryo fibroblasts), diploid cell
strains (human embryonic WI-38 and MRC-5), and few
continuous cell lines (i.e. macaque-derived Vero cells or
MDCK cells) are associated with the lowest possible risks
to the vaccine recipients. Production with such cellular
substrates often is performed in the presence of calf serum
and adherent culture with little room for optimization.
Furthermore, standardization of experiments is difficult
with primary chicken material.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Vaccinia Virus Ankara (MVA), only replicate efficiently in
avian cells [3]. Accordingly, primary chicken fibroblasts
are still a commonly accepted production substrate. As
vectored vaccines are gaining increasing importance [4],
the potential of continuous suspension cells that prolifer-
ate in chemically-defined media are attracting more and
more attention. Therefore, continuous avian cell lines are
being investigated as a viable option to replace primary
material. One possible new cell candidate that meets these
criteria is the avian designer cell line AGE1.CR.pIX (in the
following: CR.pIX) that proliferates in fully scalable sus-
pension culture and is adapted to growth in a chemically-
defined medium [5,6]. The latter property is an advantage
for metabolic flux analysis as no unknown or complex
components such as animal sera or hydrolysates that com-
plicate carbon and nitrogen balance closure are present.
Metabolic models have been developed for a variety of
cell lines to study physiological states or changes in me-
tabolism as a response to different cultivation strategies,
medium composition or stimuli like virus infection or
accumulation of toxins. For example, the human cell
lines HEK293 [7,8] and AGE1.HN [9,10], other mamma-
lian cells like CHO [11], BHK [12], MDCK [13,14] and
hybridoma cells [15,16] or insect cell lines like Sf9
[17,18] have been studied because of their relevance for
the production of biopharmaceuticals. For all these cell
lines, the two main pathways for energy generation and
precursor supply were found to be glucose catabolism
via glycolysis and glutamine catabolism via the TCA
cycle, referred to as glutaminolysis [19-21]. Therefore,
cell culture media usually contain substantial amounts
of both substrates. Associated with an overflow metabol-
ism based on glucose and a high glutaminolysis activity
is the accumulation of lactate and ammonia in the culti-
vation broth with a negative impact on cell growth and
product formation [22,23].
To describe cell metabolism, various mathematical
methods have been developed and comprehensive re-
views on applied approaches and their benefits for
mammalian cell culture research are available [24,25].
Mass balancing techniques like metabolic flux analysis
(MFA) can be performed for analysis of cellular growth,
requiring only a comparatively small set of experimental
data. During the exponential growth phase of batch cul-
tivations or continuous cultivations this method can be
used to evaluate possible intracellular flux distributions
based on measurements of exchange fluxes. However, if
the system is underdetermined, no unique flux distribu-
tion can be calculated. One approach to circumvent this
limitation is to perform 13C labelling experiments. The
higher experimental effort of such studies comes with
the advantage of an increased number of constraints
and uniquely resolvable flux distributions [26]. Anotherpossibility is to apply flux variability analysis (FVA), a
method related to MFA that calculates a flux range in-
stead of a distinct flux value [27]. The advantage of this
method is that it is experimentally less demanding as it
requires (as MFA) only extracellular metabolite and cell
concentrations as well as the biomass composition.
Intracellular flux ranges from measured extracellular
rates (uptake and release of metabolites) can then be
computed with the help of software tools such as the
CellNetAnalyzer toolbox [28].
As a starting point for studying metabolism of avian
CR.pIX cells during growth, we developed a network
model for the central metabolism oriented in size and
scope on other published models of the central metab-
olism of mammalian and insect cell lines (see Figure 1).
Pathways were selected based on entries from avian spe-
cies in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database. As it was not known whether bio-
mass composition of avian cells is comparable to other
examined cells, we first determined relative proportions
of biomass components experimentally. FVA and MFA
were then applied to assess the metabolic behaviour of
CR.pIX cells during exponential growth in a 1 L stirred
tank reactor (STR). Finally, to verify emerging hypoth-
eses regarding metabolic pathways, especially glutami-
nolysis, enzyme activity measurements and additional
growth experiments were performed.
Results and discussion
Biomass composition
To allow metabolic flux analysis, some cell characteristics
need to be known, i.e. specific dry cell weight and biomass
composition. As it was not known whether similar results
to other eukaryotic cells could be expected for an avian
cell, most characteristics were determined experimentally
rather than presumed.
The specific cell dry weight of CR.pIX cells was mea-
sured with 314 pg/cell. Amounts of DNA (2.3 ± 0.5% of
biomass) and RNA (3.1 ± 0.2%) per CR.pIX cell were com-
parable to published values obtained for other eukaryotic
cells. The protein content (55.2 ± 8.4%) was lower in CR.
pIX cells than the typical range of 70–75% determined for
other cells [7,16,29]. However, there are reports support-
ing a low protein content such as Zupke et al. who found
60% protein in mouse hybridoma cells and Carnicer et al.
who measured a protein content of only 37% for yeast
cells [30,31]. The relative amounts of amino acids of whole
cell protein determined from CR.pIX cells are in general
similar to published data on yeast [31], mammalian cells
[9,29,32] and insect cell lines [33] (see Additional file 1:
Table S1). The remaining fraction of biomass was assigned
to lipids and carbohydrates in a ratio of 1:2. The estimated
lipid content (13.1%) agrees with previous reports that vary
between 9 and 20%, whereas the assumed carbohydrate
Figure 1 Metabolic network model of the central metabolism of avian CR.pIX cells. Main parts are glycolysis (purple), amino acid
catabolism and the TCA cycle (green) which takes place in the mitochondria (grey). Reaction reversibility indicated by arrow heads. All fluxes are
given in [μmol/gDW/h]. A: shows calculated flux ranges from scenario 1 (by FVA) in square brackets, B: shows determined rate values from
scenario 2 (by MFA). The values are also given in Additional file 1: Table S2.
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3.5–25.0% reported in literature [7,16,29,30,34]. However,
a sensitivity analysis showed that absolute fractions of
lipids and carbohydrates have only a minor impact on rate
values of the calculated flux distributions (data not
shown).
Growth phases of CR.pIX cells in STR
The growth of CR.pIX cells can be divided into distinct
phases. First, an initial lag phase was observed lasting for
about 24 h with only slightly increasing viable cell concen-
trations. Thereafter, cells grew exponentially until 172 h.
Following the exponential growth phase, a reduced growth
was observed until 230 h, but viability was still above 90%
in this intermediate growth phase (Figure 2A). After hav-
ing reached the maximum viable cell concentration of
1.3 × 107 cells/mL, cell death started.
The region chosen for MFA and FVA was 24–97 h,
where a growth rate of 0.0132 h-1 was observed. In the
following, only this time frame is considered when de-
scribing and discussing extracellular rates and intracellu-
lar flux distributions as it is very likely that the quasi
steady state assumption holds. Furthermore, it is alsothe typical time frame in which cells are grown before
infection in virus production processes (MVA or influ-
enza A and B virus) [6,35]. Studies in this time frame are
therefore most relevant in terms of vaccine manufactur-
ing using CR.pIX cells.
Exchange rates from measured extracellular metabolites
Determined exchange rates of CR.pIX were compared to
rates given in other publications for mammalian cell lines
(Table 1). We chose 6 data sets where equal units were
given or could be calculated for comparison, thereof three
publications on the metabolism of human AGE1.HN cells
[9,10,36], one publication on HEK293 cells [7], and one on
MDCK cells [13]. The majority of concentration profiles
of CR.pIX cultivations are similar to concentration pro-
files obtained for other transformed cell lines studied in
the past. For most of the metabolites, the measured ex-
change rates during CR.pIX cultivation have the same
direction (uptake or release) and are in the same range
compared to those found for other cell lines. Most not-
ably, as observed for other cell lines, almost all of the
consumed glucose is converted to lactate and excreted
in the medium (Figure 2B). Key differences in the rates
Figure 2 Cultivation of CR.pIX cells in 1 L stirred tank reactor. A: viable cell concentration (■) and viability (●) with the time frame used for
MFA indicated by a pale blue box. Bands around data points indicate standard deviation from triplicate measurements. B: extracellular
concentrations glucose (■) and lactate (♦); C: extracellular concentrations of glutamine (▲) and ammonia (►). Bands around data points indicate
measurement errors from assay validations (see Additional file 1: Table S3).
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ing metabolites:
First, glutamine uptake is zero with CR.pIX cells
(Figure 2C) as the observed glutamine concentration de-
crease is solely due to glutamine hydrolysis. Associated
with this, only low amounts of ammonia accumulated in
the medium (1.4 mM after 97 h: maximal 2.8 mM at the
end of the batch cultivation at 210 h). For production of
cell culture-derived products this is a beneficial character-
istic as higher ammonia concentrations are known to be
toxic with negative impact on cell growth and product for-
mation [22]. The observed ammonia concentration is at
the lower limit compared to other cells, where concentra-
tions between 3 and 8 mM were reported to lead to im-
paired growth [37-39].
The second difference is observable for glycine which
is taken up by CR.pIX cells, but released by other cell
lines. This observation can be explained by the fact that
glycine is reported to be an essential amino acid for
birds and therefore needs to be provided for CR.pIX
cells by the medium [40]. The third finding is thataspartate and asparagine are consumed by CR.pIX cells
in higher amounts or at least at higher rates compared
to other cell lines. Both amino acids can be converted to
oxaloacetate and thus channeled into the TCA cycle.
One could hypothesize that CR.pIX cells compensate in
that way for the negligible glutamine uptake to fill the
TCA cycle intermediate pools. We also observed that
the measured uptake rates for the essential amino acids
histidine, lysine and tryptophan were slightly below their
minimal requirements for biomass formation with the
determined growth rate. For the following analyses we
therefore adjusted their upper boundaries slightly to fit
the minimal stoichiometric demands for the measured
specific growth rate.
Intracellular flux distribution
Using a metabolic network model of the central metab-
olism of avian cells that we developed according to
literature data and database entries, the metabolism of
CR.pIX cells during cultivation in 1 L STR was studied
using FVA (details see section “Flux variability and
Table 1 Determined extracellular fluxes for cultivation of CR.pIX cells in comparison with literature data
CR.pIX STR AGE1.hn Shakera AGE1.hn Tubeb AGE1.hn Tubec HEK293 STRd,f MDCK STRe,f
Time frame 24–97 h 18–90 h 72–169 h 0–74 h 0–72 h 16–80 h
Initial glc conc. [mM] 33 20–25 30 30 15 30
Initial gln conc. [mM] 1.5 5 2 4 1 2
Glc -211.2 ± 10.8g -123.0 -126.9 -429.2 -395.5 -1108.7
Lac 297.6 ± 8.8 263.3 87.6 639.8 439.0 2108.0
Pyr -30.1 ± 0.8 -28.7 -2.9 -76.5 - 0.0
Gln -0.1 ± 0.1 -37.1 -41.2 -95.5 -66.5 -70.9
Amm 12.6 ± 0.9 - - 91.7 48.5 51.8
Glu -1.4 ± 1.1 4.0 0.9 17.0 -1.4 -42.1
Ala 31.6 ± 4.9 17.5 8.0 20.6 11.8 -49.4
Arg -9.9 ± 2.8 -8.2 -4.4 -12.4 -15.3 -11.7
Asn -17.1 ± 8.5 -2.9 -2.0 -7.3 -4.6 -1.9
Asp -17.8 ± 3.2 -14.1 -8.9 -16.2 -0.2 -2.0
Cys 0.0 0.2 -1.1 -0.2 - -2.4
Gly -4.8 ± 4.8 2.6 -0.8 6.8 17.0 2.3
His -2.3 ± 0.4 -1.7 -0.7 -3.2 -3.5 -2.8
Ile -6.2 ± 4.4 -8.1 -1.4 -14.7 -21.8 -12.3
Leu -7.9 ± 3.2 -11.5 -3.2 -23.8 -24.7 -23.5
Lys -5.5 ± 0.3 -6.9 -3.5 -16.6 -12.6 -22.9
Met -4.1 ± 2.0 -3.1 -1.2 -6.6 -4.9 -6.4
Phe -2.5 ± 1.0 -3.3 -1.5 -6.3 -5.4 -8.9
Pro -0.1 ± 0.1 7.1 13.1 13.4 0.8 6.7
Ser -8.3 ± 8.3 -12.2 -5.7 -33.4 -17.7 -16.8
Thr -3.4 ± 1.9 -4.9 -2.0 -8.0 -9.5 -14.9
Trp -1.5 ± 0.2 -0.9 -0.4 -0.8 - -5.2
Tyr -1.8 ± 1.8 -2.8 -1.4 -5.5 -4.6 -5.0
Val -4.3 ± 2.8 -8.4 -1.8 -14.2 -19.1 -17.0
Uric acid 0.0 - - - - -
All rates are given in μmol/gDW/h.
afrom [9]; bfrom [36]; cfrom [10]; dfrom [7]; efrom [13,14].
fthese fluxes were re-calculated to [μmol/gDW/h] with the given fluxes and cell dry weights.
gstandard deviation from Monte-Carlo sampling using validated standard deviations of the methods as boundaries.
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97 h was chosen for analysis, as within this time interval
during exponential growth, the quasi steady state as-
sumption holds. FVA uses as few constraints for the
metabolic network as possible in order to get an un-
biased look at the metabolism. This generated a distri-
bution of flux ranges that is named scenario 1 in this
manuscript. However, flux ranges are sometimes difficult
to interpret. Therefore, after having performed FVA, we
set few reasonable constraints, e.g. uptake and excretion
rates were set as fixed and the pyruvate carboxylase ac-
tivity was assumed to be inactive. With these constraints
a unique flux distribution could be calculated which is
discussed as scenario 2 in the following.All calculated flux ranges (scenario 1; determined by
FVA) and fluxes (for scenario 2, determined by MFA) are
given in the Additional file (Additional file 1: Table S2).
Together with the network, main fluxes are also depicted
in Figure 1. Although only flux ranges can be calculated
with the constraints of scenario 1 (Figure 1A), some con-
clusions can already be drawn from them as we will dis-
cuss below. However, most of the following discussion will
refer to the unique flux distribution calculated for scenario
2 (Figure 1B). With the applied constraints, the linear
equation system had two degrees of redundancy. There-
fore, the sum of the variance weighted squared residuals
(h) need to be below 5.99 to exclude significant measure-
ment errors (with an applied significance level of α = 0.05).
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the model fitted the data sufficiently well.
Glycolysis and cytosolic pyruvate metabolism
Glucose is taken up with a high rate (211 μmol/gDW/h)
and then processed via glycolytic reactions to pyruvate.
Only 1% of the glucose is fed into the pentose phosphate
pathway for nucleotide synthesis. Such low pentose phos-
phate influxes were also observed in other studies with
transformed cells, e.g. 1.5% and 2.9% in human AGE1.HN
cells [9,36]. The calculated ranges for the rates of glycoly-
sis are relatively narrow as they mainly depend on the glu-
cose uptake rate that was given by the measurement of
extracellular glucose. Cytosolic pyruvate is mainly derived
from glycolysis (92%); the rest of the cytoplasmic pyruvate
is taken up by the cells and in small parts obtained from
cysteine degradation and the malic enzyme reaction (to-
gether 1%). Similar to other transformed cells, cytosolic
pyruvate is mainly converted to lactate (73%) or alanine
(10%). Only a small fraction (16%) is transported to the
mitochondria where it is converted to acetyl-CoA and fur-
ther oxidized. However, if a complete pentose phosphate
pathway (PPP) is included in the model, the exact ratio be-
tween glycolysis and PPP is unresolvable and the corre-
sponding flux ranges would be notably wider. Since CO2
is produced via the PPP, a high PPP flux would reduce
the amount of carbon that re-enters the lower part of
glycolysis, and therefore even less pyruvate would enter
the TCA cycle.
In general, the flux distribution at the cytosolic pyruvate
node shows that the majority of the glucose-associated
metabolism of CR.pIX cells is used to generate ATP and
reducing equivalents via glycolysis. The known Warburg
effect of enhanced aerobic glycolysis, leading mostly to
lactate, can thus also be observed in transformed cells
from avian origin. Furthermore, there seems to be a weak
coupling to the mitochondrial TCA cycle as only a mi-
nority of the cytosolic pyruvate is channeled into the
mitochondria. Other studies have shown that several
transformed cell lines show low activities of the three
pyruvate dependent enzymes pyruvate dehydrogenase
(PDH), pyruvate decarboxylase (PC) and phosphoenol-
pyruvate carboxykinase (PEPCK) that can serve as con-
nectors between glycolysis and TCA cycle [41,42]. For
our cells, we calculated that the PDH (r33) must carry
some flux (since the lower boundary of this reaction is
strictly positive), but the non-resolvable PC reaction
(r46) is not obligatory as its flux range also includes
zero. Measurements on activities of anaplerotic en-
zymes will be discussed in a later subsection.
Mitochondrial pyruvate metabolism and TCA cycle
The mitochondrial pyruvate pool is fed from the cyto-
solic pyruvate pool (64%) and the anaplerotic malateconversion (34%). 100% of the efflux is catalyzed by the
pyruvate dehydrogenase thereby generating 88% of the
mitochondrial acetyl-CoA. Other influxes towards this
TCA precursor come from amino acids, namely isoleucine
(4%) and leucine (7%), tryptophan, and lysine (together
1%). The subsequent reactions of the TCA cycle are fed
from other catabolic reactions: α-ketoglutarate from cyto-
solic influx and succinyl-CoA from isoleucine, valine,
serine and methionine degradation. This shows the de-
pendency of the TCA cycle activity on relatively high
amino acid uptake and catabolic rates in CR.pIX cells.
Oxidative phosphorylation & ATP balance
We calculated high fluxes for the oxidation of NADH
(177 μmol/gDW/h) and FADH2 (46 μmol/gDW/h). Since
a transport reaction for NADH between the cytosol and
mitochondria was included in the model, the pools of re-
ducing equivalents for both compartments are balanced
simultaneously. A minor flux for the corresponding trans-
port reaction shifting reducing equivalents from the mi-
tochondria to the cytosol was calculated with 30 μmol/
gDW/h. By setting this transport reaction to zero, cyto-
solic and mitochondrial reducing equivalents have to be
balanced separately. Besides an increased oxygen uptake
and ATP synthesis rate, this leads to no significant differ-
ences in the flux distributions (data not shown).
ATP generation via the TCA cycle and the electron
transport chain makes up to 74% of the total ATP gener-
ated. A smaller fraction (26%) is derived from glycolysis.
This is similar to results from studies on mouse hybridoma
and CHO cells [43,44] where values of 60–80% of ATP
production via the TCA cycle have been reported. Al-
though considerable ATP amounts are needed for lipid
synthesis, amino acid transporters, upper glycolysis and
biomass, the high (unspecific) ATP consumption through
reaction r77 (966 μmol/gDW/h) indicates that there seems
to be an overload with ATP which is either used for certain
maintenance processes or passed through futile cycles.
Amino acid and nitrogen metabolism
Degradation rates of some amino acids, e.g. tryptophan
and histidine, are low, indicating that these amino acids
are taken up to match the anabolic demand for synthesiz-
ing biomass rather than to further metabolize them via
catabolic routes. The calculated rate ranges for most fluxes
of the amino acid catabolism are constrained to relatively
small intervals (e.g. for degradation of valine and histi-
dine). There is no uric acid synthesis (r68) as no uric acid
could be measured experimentally. Although this reaction
is known to take place in avian cells, this is not a fully un-
expected finding. Uric acid was detected in livers and kid-
neys of chicken and turkey, but not in all bird tissues [40].
CR.pIX cells, as other transformed cells, use ammonia as a
sink and release the excess cytosolic ammonia (that is
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the medium where it accumulates. However, due to low
glutamine exploitation, the ammonium concentration
stays at a low level so that toxic concentrations are not
reached.
Interestingly, the fluxes through the glutamine synthe-
tase (r48) (i.e. in the direction of glutamate synthesis)
are negative as glutamine uptake was not sufficient for
biomass synthesis and glutamine therefore has to be syn-
thesized from the glutamate pool. Glutamate itself is
likely to be mainly derived from degradation reactions of
isoleucine, valine and aspartate. Especially aspartate is
taken up in large parts (18 μmol/gDW/h) and can be
converted to glutamate. Other amino acids that could
compensate for glutamine conversion to glutamate are
arginine, histidine and proline. However, only arginine is
taken up in considerable amounts by the cells so that
one could speculate that the path from glutamate to α-
ketoglutarate is generally not used extensively by the CR.
pIX cells and thus, the classical dependency on glutam-
ine is not given for CR.pIX cells. To elucidate unambigu-
ously the source of carbon for glutamate synthesis, 13C
labelling experiments would be required, which are be-
yond the scope of the current contribution.
In vitro enzyme activities
To validate the two hypotheses from the previous section
that i) glycolysis is only weakly connected to the TCA, and
that ii) glutaminolysis plays a minor role in energy supply
and precursor generation, we measured the maximum
in vitro enzyme activities of the related enzymes.
For the first hypothesis, we measured maximum activ-
ities of PC and PDH. For both reactions, low enzyme ac-
tivities of 0.2 nmol/106cells/min (i.e. 39 μmol/gDW/h)
were measured as for MDCK cells [45]. These values
supported the applied constraint of a missing carboxylat-
ing anaplerotic reaction from pyruvate towards oxaloac-
etate. However, the measured low PDH activity seems to
contradict the calculated flux of 102 μmol/gDW/h. One
possible explanation is given by the significantly smaller
calculated lower boundary of this flux when applying
fewer and less stringent assumptions with scenario 1.
However, at least a basal activity is required as the lower
boundary is strictly positive (53 μmol/gDW/h).
The second hypothesis, stating that glutaminolysis is
inversed, was validated via measurements of glutaminase
(converting glutamine to glutamate) and glutamine syn-
thetase (converting glutamate to glutamine). Glutamin-
ase showed a maximal activity of 0.1 nmol/106cells/min
(i.e. 19 μmol/gDW/h), which is an even lower value than
the measured 1.5–7.4 nmol/106cells/min for MDCK
cells [45,46]. The flux from glutamate to glutamine was
predicted by flux analysis to be active towards glutamine
in order to account for the unmet demand of glutaminefor biomass formation. The measured enzyme activity of
the catalyzing enzyme glutamine synthetase showed a
maximal activity of 5.9 nmol/106cells/min (i.e. 1135 μmol/
gDW/h). This value is on the one hand significantly higher
than the value for the reverse reaction and on the other
hand at the upper limit of reported values for MDCK
cells (0.6–6.5 nmol/106cells/min, [45,46]). Thus, although
values from in vitro enzyme activity measurement and flux
analysis are not directly convertible, the measured enzyme
activities support the calculated flux distribution towards
glutamine and the low level of glutamine usage.
Growth in glutamine-free medium
Since the uptake flux for glutamine was calculated as
zero and the enzyme measurements supported the low
glutaminolytic activity, we speculated whether glutam-
ine is even dispensable for growth of CR.pIX cells. To
validate this hypothesis, we performed shaker flask cul-
tivations of CR.pIX cells in CD-U2 medium with 2 mM
glutamine and in CD-U2 medium without glutamine
addition. As no serum is present in the medium, other
glutamine sources can be excluded. Cultures with or
without glutamine were run in parallel over 5 passages.
For passage 5, a growth curve was recorded. Figure 3
shows that cells without glutamine did not grow as well
as in the presence of glutamine during the first three
passages (Figure 3A). Viability also dropped below 90%
in these cultures (Figure 3B). After passage 3, cell growth
performance in glutamine-free medium increased sig-
nificantly. Finally, cells in the 5th passage in glutamine-
free medium did grow comparably fast as in the presence
of glutamine. Maximal viable cell concentrations of
1.4 × 107 cells/mL were achieved with viabilities above
90%. This experiment demonstrated that CR.pIX cells
are capable of glutamine-independent growth. With
CHO cells, this was achieved after several selection
rounds [47], but could not be achieved with other cells
[48,49]. Considering that we did not measure glutamine
uptake fluxes, we were surprised at the intermittent de-
crease in proliferation rates and viabilities of CR.pIX
cultures after glutamine removal. However, extracellular
and intracellular glutamine mediate also non-nutritional
effects that can impact apoptosis and heat shock re-
sponses [50,51]. We hypothesize that the short adapta-
tion period after glutamine removal may be due to
shifts in glutamine-responsive signaling pathways. In-
fection experiments with poxvirus MVA showed that
productivity of CR.pIX cells is not negatively affected
by glutamine absence (data not shown). The feature of
glutamine-free growth of CR.pIX cells may be advanta-
geous in particular for high cell density cultivations were
ammonia accumulates to very high concentrations in the
culture supernatant and prevents further increases in cell
numbers and productivity [38,52].
Figure 3 Cultivation of CR.pIX cells with (black squares) or without glutamine (orange triangles) in shaker flasks (two parallel cultures each).
Viable cell concentrations (A) and viabilities (B) are shown for 5 subsequent passages of CR.pIX cells in the respective medium. The pale blue box
highlights the 5th passage for which a growth curve was monitored.
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Avian cells are important substrates for producing a num-
ber of licensed vaccines and various viral vector-based
processes under development. The only avian substrates
that are currently approved for production are embryo-
nated chicken eggs or primary chicken embryo fibroblasts.
Because processes using primary cultures are difficult to
optimize and standardize, access to well characterized
continuous avian cell lines, such as the CR.pIX cell line
derived from a muscovy duck embryo, would be a signifi-
cant step forward.
Here, we determined metabolic properties of the
CR.pIX cell line to complement previous developments on
scalable vaccine production processes in chemically de-
fined media. The current study comprised three parts: i)
analysis of biomass composition and measurements of cell
and extracellular metabolite concentrations, ii) construc-
tion of a stoichiometric network for the central metabol-
ism of avian cells and subsequent analysis with flux
variability and metabolic flux analysis, and iii) experiments
and analytics to validate hypotheses derived from the stoi-
chiometric analysis.
The first part expands the available data base on the
metabolism of immortalized cell lines. Results on bio-
mass composition and growth properties of the avian
CR.pIX cell line agree with data determined for other
transformed mammalian and insect cell lines used in
biopharmaceutical production.
Flux variability and metabolic flux analyses in the sec-
ond part reveal an overflow metabolism similar to mam-
malian cells with high uptake of glucose followed by
conversion to and release of lactate and alanine. The
TCA cycle was only weakly connected to glycolysis andappeared to depend on the influx of amino acids, mainly
isoleucine, valine and aspartate. Finally, our measure-
ments together with flux (variability) analysis indicated
that glutamine supplementation is not an essential re-
quirement for CR.pIX cell proliferation.
The derived hypothesis on low glutaminolysis activity
could be confirmed by enzyme activity measurements.
However, the hypothesis of a weak connection between
the cytosolic and mitochondrial pyruvate pools could
not be confirmed entirely. To elucidate whether cytosolic
pyruvate is transported in significant amounts from the
cytosol to the mitochondria, e.g. 13C labelling experiments
could be helpful, which was beyond the scope of the
current contribution. Low dependence on glutamine was
confirmed by passaging cells in glutamine-free medium
and agrees well with the observation that ammonia is ac-
cumulating to very low concentrations in the medium.
This is a very beneficial property of CR.pIX cells especially
for fed-batch cultivation strategies where ammonia often
accumulates to toxic levels.
Overall, the present study provides a basis for a more
focused metabolic analysis of avian cell lines and thus
helps to further optimize medium and feed require-
ments. Acute infection and associated take-over of the
metabolism by a virus may shift the requirements for
certain nutrients. The derived model may therefore also
provide a context for future studies on the metabolism
of CR.pIX cells during the virus replication phase.
Methods
Cell cultivations
CR.pIX suspension cells were routinely cultivated in
250 mL shaker flasks (working volume 150 mL, with
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medium (CD-U2, PAA) supplemented with glutamine
(2 mM final concentration, Sigma), alanine (2 mM final
concentration, Sigma) and a recombinant insulin-like
growth factor (Long-R3 IGF, 10 ng/mL final concentra-
tion, Sigma). Flasks were incubated at 185 rpm with
5 cm amplitude, 37°C and 5% CO2. Pre-cultures for bio-
reactor experiments, cultures for determination of bio-
mass composition as well as the comparative cultivations
in glutamine-containing and glutamine-free medium were
performed in shaker flasks. For inoculation of a 1 L stirred
tank bioreactor (STR, DasGip AG, vessel: Spinner Type
BS, cellferm-pro® system), 8 × 105 cells/mL in 1 L CD-U2
medium were transferred into the bioreactor. The bio-
reactor was equipped with a pitched-blade stirrer that
was operated at 120 rpm. The temperature was con-
trolled at 37°C; pO2 was set to 50% by pulsed aeration
with air enriched with variable contents of O2 and CO2.
During the first 60 h, pH was slowly reduced from 7.4 (ini-
tial value of the medium) to 7.0 and controlled at this
value subsequently by addition of CO2 or 1 M Na2CO3.
Measurement of biomass composition
All assays and analytics were performed with cells in the
exponential growth phase. Therefore, samples were taken
from shaker flask cultures at 72 h post inoculation. For
each analysis, 3 biological replicates were measured with
at least 3 technical replicates each.
For determination of dry cell weight, cell suspension
containing about 1 × 108 cells/mL was centrifuged (500 × g,
10 min) and re-suspended in 10 mL of fresh medium.
Samples were dried at 60°C until weight remained con-
stant. The specific dry cell weight was calculated against
weight of empty tubes and against a medium control
(10 mL of fresh medium dried in tubes).
The BCA assay (Pierce/ThermoScientific) was used to
determine the cellular protein content. Samples containing
4 × 106 cells were centrifuged (500 × g, 10 min) and re-
suspended in 1 mL lysis buffer (from CytoTox 96® Non-
Radioactive Cytotoxicity Assay, Promega). After 15 min
incubation at room temperature, samples were sonicated
for 3 min in a water bath. Standard curves were prepared
using BSA and analyzed together with samples by measur-
ing the absorption at 562 nm (inifinite200 plate reader,
TecanGroup).
For DNA purification, a culture volume containing
5 × 106 cells was taken and purified with the QIAamp
DNA Blood Mini kit (Qiagen) according to the proced-
ure “protocol for cultured cells”. After purification, 2 μL
of assay buffer (in which the samples were dissolved
later) were pipetted onto 16 spots on a NanoQuantPlate
(TecanGroup) as blank. After blanking, 2 μL of samples
were measured. DNA concentration was then deter-
mined by multiplication of the measured absorptioncoefficient with 50 as a dsDNA specific factor. The same
method as for DNA content analysis was employed for
RNA content analysis. Here, purification was done with
the NucleoSpin RNAII kit (Macherey-Nagel) according
to the procedure “total RNA purification from cultured
cells and tissue”. RNA concentration was determined
from absorption measurements at 260 nm, but by multi-
plication with a factor of 40. Measurement procedure
was analogous to the DNA analysis.
Amino acid contents were determined as follows:
about 1 × 108 cells were washed with 0.9% NaCl solution
and re-suspended in 2 M HCl. Cells were incubated in
acid at 100°C for 24 h. After this hydrolyzation, the solu-
tion was neutralized by adding 2 M NaOH and subse-
quently analysed by HPLC. Aspartate and glutamate
percentages were corrected for a hydrolysis rate of 47.5%
as described in literature [7].
A HPLC method was used to measure the amino acid
composition of cell protein [53]. Due to harsh hydrolytic
conditions, some amino acid concentrations could not
be measured, but were estimated from literature values
(see Additional file 1: Table S1).
Cell and metabolite concentration measurements
Samples were taken once or twice a day. Cell concentra-
tion, viability and average cell diameter were determined
using the Vi-CELL™ XR device (Beckman Coulter). Sam-
ples for measuring extracellular metabolite concentrations
were centrifuged after sampling and the supernatant was
stored at -80°C until analysis. Measurement of glucose,
lactate and ammonia concentrations was done with a Bio-
profile 100 Plus (Nova Biomedical). A HPLC method was
used to measure the concentration of pyruvate. Extracellu-
lar amino acid concentrations for metabolic flux analysis
were determined using a derivatization method and subse-
quent measurement in a HPLC system [54]. Uric acid con-
centration was measured with an enzymatic reaction assay
kit (Uric Acid Assay Kit, BioVision) including standard
curves and controls as described in the manual. Uric acid
was only measured at culture start and end. Standard
deviations for all concentration measurements (deter-
mined by method validations) can be found in Additional
file 1: Table S3.
In vitro determination of maximum enzyme activities
Maximum activities of pyruvate carboxylase (PC), pyru-
vate dehydrogenase (PDH), glutamine synthetase (GS)
and glutaminase (GLNase) in exponentially growing cells
were measured. Therefore, cells were harvested from
shaker flasks 72 h after inoculation. After a washing step
in 0.9% NaCl, dry cell pellets were frozen at -80°C and
stored until analysis. Enzyme extraction and assays were
performed as described for MDCK cells [46]. Three
assay parameters had to be optimized before measuring
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and – for GLNase and GS activity assay – incubation
time. After these pre-tests, CR.pIX cell extracts were
measured with the following modifications: a two-fold
higher cell concentration as for MDCK cells was neces-
sary for the GLNase and GS assay and the incubation
time of the GLNase assay was set to 30 min instead of
60 min. The assay plates were analyzed in a 96 well plate
reader (Tecan) and enzyme activities were calculated
from absorption values.
Metabolic network
A stoichiometric network model of the central metabol-
ism of avian cells (Figure 1, Table 2) was constructed
based on KEGG database entries from Gallus gallus
(chicken), Meleagris gallopavo (turkey) and Taeniopygia
guttata (zebra finch) as well as on information available
from previously published networks and from studies on
avian metabolism [40]. Overall, the network consists of
97 reactions and 72 metabolites, resulting in a stoichio-
metric matrix with dimensions 72 × 97 and 28 degrees of
freedom. All implemented reactions are listed in the
Table 2.
Generally, the network includes
 Two compartments: cytosol and mitochondria
 Main pathways of energy metabolism: glycolysis,
TCA cycle and oxidative phosphorylation
 Catabolism of amino acids
 Transport of metabolites and corresponding energy
demands (as described before [14])
 Synthesis of macromolecules (biomass)
 Synthesis of urea and uric acid
 A simplified/lumped pentose-phosphate pathway
(as in [9])
Calculation of extracellular rates
During the exponential growth phase, metabolism is
considered to be in a pseudo steady-state with constant
reaction rates [55]. The growth rate μ was calculated via
curve fitting of the viable cell concentration measure-
ments (X(t)) to:
X tð Þ ¼ X t0ð Þ⋅eμ⋅ t−t0ð Þ ð1Þ
Uptake or release rates vi (in unit [μmol/gDW/h] of
external metabolites ci were computed via curve fitting
of the concentration data to:
ci tð Þ ¼ ci toð Þ þ νi⋅DW t0ð Þ
μ
⋅ eμ⋅ t−t0ð Þ−1
 
; ð2Þ
where we applied the experimentally determined cell
dry weight and the calculated μ from Equation (1).For glutamine, a first order degradation process to
ammonia and 5-oxopyrrolidine-2-carboxylic acid was
assumed. The rate constant kGln = 0.0032 h
-1 of this
process was determined experimentally (n = 3) using
medium without cells under standard cultivation condi-
tions in a bioreactor. Based on this degradation rate, glu-
tamine and ammonia rates (Equation (2)) were corrected
as described elsewhere [56]. To compute standard devia-
tions of the fluxes, we performed a Monte-Carlo simula-
tion and added a normally distributed error with mean
zero and corresponding standard deviation (derived
from assay validations) at each time point and for each
measurement (metabolites and cell concentration). With
this, we generated 100,000 random sample data sets and
recalculated for each data set the rates of uptake, release
and growth. From these simulated data sets, the empir-
ical variances and standard deviations σri for each of
these rates were computed.
Flux variability and metabolic flux analysis
We restrict our analysis to the time span of exponential
growth from 24 h to 97 h. Within this time interval the
quasi steady state assumption holds and, together with
the stoichiometric matrix N and the vector r of reaction
rates (fluxes), the reaction rates can be determined by
solving a system of linear equations. Given the measured
and known rates, r and N can be partitioned into the
known (rk, Nk) and unknown part (ru, Nu) we can write
the steady state equation as
dc
dt
¼ 0 ¼ N⋅r ¼ Nuru þNkrk
yielding after reformulation the central equation for
metabolic flux analysis
Nuru ¼ −Nkrk: ð3Þ
A detailed description of how to further proceed with
Equation (3) is given elsewhere [57-59]. If the linear equa-
tion system is over-determined, a variance-weighted least
squares estimation can be applied to calculate uniquely
determined reaction rates. However, Equation (3) usually
defines an underdetermined system and, hence, the flux
distribution cannot be calculated uniquely. For identifying
at least feasible ranges of the fluxes we use flux variability
analysis (FVA), an approach that is based on linear pro-
gramming [27]. Here, the minimal and maximal possible
flux that a reaction can have in any flux distribution that is
consistent with Equation (3) is calculated separately for
each unknown reaction ru,i,. Further constraints arise by
the irreversibility of some reactions (constrained to non-
negative values) or because some reaction rates are fixed
to specific (measured or known) values reflecting the given
environmental conditions. To avoid unbounded fluxes and
Table 2 Reactions included in the metabolic network
model of CR.pIX cells
Uptake rates
r1, Glc Glc→ Glccyt
r2, Pyr Pyr + 0.33 ATPcyt→ Pyrcyt
r3, O2 O2→O2,cyt
r4, Gln Gln + 0.33 ATPcyt→ Glncyt
r5, Glu Glu + ATPcyt→ Glucyt
r6, Ala Ala + 0.33 ATPcyt→ Alacyt
r7, Asp Asp + ATPcyt→ Aspcyt
r8, Arg Arg + 0.33 ATPcyt→ Argcyt
r9, Asn Asn + 0.33 ATPcyt→ Asncyt
r10, Cys Cys + 0.33 ATPcyt→ Cyscyt
r11, Gly Gly + 0.33 ATPcyt→ Glycyt
r12, His His + 0.33 ATPcyt→ Hiscyt
r13, Ile Ile + 0.33 ATPcyt→ Ilecyt
r14, Leu Leu + 0.33 ATPcyt→ Leucyt
r15, Lys Lys + 0.33 ATPcyt→ Lyscyt
r16, Val Val + 0.33 ATPcyt→ Valcyt
r17, Met Met + 0.33 ATPcyt→Metcyt
r18, Phe Phe + 0.33 ATPcyt→ Phecyt
r19, Pro Pro + 0.33 ATPcyt→ Procyt
r20, Ser Ser + 0.33 ATPcyt→ Sercyt
r21, Thr Thr + 0.33 ATPcyt→ Thrcyt
r22, Trp Trp + 0.33 ATPcyt→ Trpcyt
r23, Tyr Tyr + 0.33 ATPcyt→ Tyrcyt
Glycolysis
r24, G6P Glccyt + ATPcyt→ G6Pcyt
r25, F6P G6Pcyt ↔ F6Pcyt
r26, FBP F6Pcyt + ATPcyt ↔ FBPcyt
r27, DHAP FBPcyt ↔ GAPcyt + DHAPcyt
r28, GAP DHAPcyt ↔ GAPcyt
r29, PG GAPcyt ↔ NADHcyt + ATPcyt + PGcyt
r30, PEP PGcyt↔ PEPcyt
r31, PEP_Pyr PEPcyt→ Pyrcyt + ATPcyt
r32, Pyr_Lac Pyrcyt + NADHcyt ↔ Laccyt
r33, PDH Pyrmit + CoAmit→ AcCoAmit + CO2,mit + NADHmit
Pentose phosphate pathway
r34, R5P G6Pcyt→ R5Pcyt + CO2,cyt + 2 NADPHcyt
TCA cycle
r35, OAA Malcyt ↔ OAAcyt + NADHcyt
r36, Cit AcCoAcyt + OAAcyt→ Citcyt + CoAcyt
r37, Fum_Mal Fumcyt ↔ Malcyt
r38, Citmito AcCoAmit + OAAmit→ Citmit + CoAmit
r39, OAAmito Malmit↔ OAAmit + NADHmit
r40, Fum_Malmito Fummit↔ Malmit
Table 2 Reactions included in the metabolic network
model of CR.pIX cells (Continued)
r41, SCoAmito aKGmit + CoAmit→ SuccCoAmit + CO2,mit + NADHmit
r42, Fummito SuccCoAmit↔ Fummit + CoAmit + ATPmit + FADH2,mit
r43, aKGmito Citmit↔ aKGmit + CO2,mit + NADHmit
Anaplerosis
r44, Ana_PyrI Malcyt→ Pyrcyt + CO2,cyt + NADPHcyt
r45, Ana_PyrII Malmit↔ Pyrmit + CO2,mit + NADPHmit
r46, PC Pyrmit + CO2,mit + ATPmit→OAAmit
Amino acid catabolism
r47, GDH Glumit↔ aKGmit + Ammmit + NADPHmit
r48, GS Glncyt ↔ Glucyt + Ammcyt + ATPcyt
r49, Alacat Alacyt + aKGcyt ↔ Pyrcyt + Glucyt
r50, Asn_Asp Asncyt ↔ Aspcyt + Ammcyt
r51, Hiscat Hiscyt→ Glucyt + 2 Ammcyt + CO2,cyt
r52, Ilecat Ilecyt + aKGcyt + 2 CoAmit + ATPmit→ SuccCoAmit +
AcCoAmit + Glucyt + NADHmit + FADH2,mit
r53, Leucat Leucyt + aKGcyt + 3 CoAmit + 2 ATPmit→ 3 AcCoAmit +
Glucyt + NADHmit + FADH2,mit
r54, Lyscat Lyscyt + 2 aKGcyt + 2 CoAmit + NADPHcyt→ 2 AcCoAmit +
2 Glucyt + 2 CO2,mit + 2 NADHcyt + 2 NADHmit + FADH2,mit
r55, Metcat Metcyt + Sercyt + CoAmit + 3 ATPcyt + ATPmit→ Cyscyt +
SuccCoAmit + Ammcyt + NADHmit + CO2,cyt
r56, Phecat Phecyt + O2,cyt + NADPHcyt→ Tyrcyt
r57, Procat Procyt ↔ Glucyt + 2 NADHcyt
r58, Thrcat Thrcyt→ Pyrmit + Ammmit + CO2,mit + NADHcyt +
NADHmit + FADH2,mit
r59, Trpcat Trpcyt + 2 CoAmit + 3 O2,cyt + NADPHcyt→ Alacyt + 2
AcCoAmit + Ammcyt + 2 CO2,mit + 2 CO2,cyt + NADHcyt +
2 NADHmit + FADH2,mit
r60, Valcat Valcyt + aKGcyt + CoAmit + ATPmit→ SuccCoAmit + Glucyt +
CO2,cyt + 3 NADHmit + FADH2,mit
r61, Tyrcat Tyrcyt + aKGcyt + 2 CoAcyt + 2 O2,cyt→ Fumcyt + 2
AcCoAcyt + Glucyt + CO2,cyt
r62, Sercat Sercyt ↔ Pyrcyt + Ammcyt
r63, Cyscat Cyscyt + aKGcyt + O2,cyt→ Pyrcyt + Glucyt
r64, Aspcat Aspcyt + aKGmit↔ Glucyt + OAAmit
r65, Argcat Argcyt + aKGcyt→ 2 Glucyt + Ureacyt + NADHcyt
MTHF & uric acid synthesis
r66, MTHF_I Sercyt + THFcyt→ Glycyt + MTHFcyt
r67, MTHF_II Glycyt + THFcyt→NADHcyt + CO2,cyt + Ammcyt +MTHFcyt
r68, UricAcid Aspcyt + 2 Glncyt + Glycyt + 2 MTHFcyt + 7 ATPcyt +
CO2,cyt→ UricAcidcyt + Fumcyt + 2 Glucyt + 2 THFcyt
Lipid synthesis
r69, CHLip 18 AcCoAcyt + 18 ATPcyt + 11 O2,cyt + 27 NADPHcyt→
CH + 18 CoAcyt + 9 CO2,cyt
r70, PCLip GAPcyt + Sercyt + 27.6 ATPcyt + 17.6 AcCoAcyt + 4
MTHFcyt + 2 NADHcyt + 31.2 NADPHcyt→ PC + 17.6
CoAcyt + 4 THFcyt
r71, PELip GAPcyt + Sercyt + 18.6 ATPcyt + 17.6 AcCoAcyt +MTHFcyt +
2 NADHcyt + 31.2 NADPHcyt→ PE + 17.6 CoAcyt + THFcyt
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Table 2 Reactions included in the metabolic network
model of CR.pIX cells (Continued)
r72, PSLip GAPcyt + Sercyt + 18.6 ATPcyt + 17.6 AcCoAcyt + 2 MTHFcyt +
2 NADHcyt + 31.2 NADPHcyt→ PS+ 17.6 CoAcyt + 2 THFcyt
r73, PGLLip 2 GAPcyt + 17.6 ATPcyt + 17.6 AcCoAcyt + 4 NADHcyt +
31.2 NADPHcyt→ PGL + 17.6 CoAcyt
r74, PILip GAPcyt + G6Pcyt + 17.6 ATPcyt + 17.6 AcCoAcyt +
2 NADHcyt + 31.2 NADPHcyt→ PI + 17.6 CoAcyt
r75, SMLip 2 Sercyt + 27.8 ATPcyt + 16.8 AcCoAcyt + 3 MTHFcyt + 2
NADHcyt + 29.6 NADPHcyt→ SM+ 16.8 CoAcyt + 3 THFcyt
r76, DPGLip 3 GAPcyt + 35.2 ATPcyt + 35.2 AcCoAcyt + 6 NADHcyt +
62.4 NADPHcyt→DPG + 35.2 CoAcyt
Release rates
r77, ATPmain ATPcyt→maintenance
r78, Lacout Laccyt→ Lac
r79, Alaout Alacyt→ Ala
r80, UricAcidout Uric acidcyt→ Uric acid
r81, Ureaout Ureacyt→ Urea
r82, Ammout Ammcyt→ Amm
r83, CO2 out CO2,cyt→ CO2
r84, Pyrout Pyrcyt→ Pyr
Transport reactions, oxidative phosphorylation
r85, NADHcyt,trans NADHcyt ↔ NADHmit
r86, ATPtrans ATPcyt ↔ ATPmitt
r87, CO2 trans CO2,cyt↔ CO2,mit
r88, MALtrans Malcyt + Citmit ↔ Malmit + Citcyt
r89, Glutrans Glucyt ↔ Glumit
r90, Pyrtrans Pyrcyt ↔ Pyrmit
r91, aKGtrans aKGcyt ↔ aKGmit
r92, Ammtrans Ammcyt↔ Ammmit
r93, FADHox O2,cyt + 2 FADH2,mit→ 3 ATPmit
r94, NADHmit,trans NADHmit↔ NADPHmit
r95, NADHox O2,cyt + 2 NADHmit→ 5 ATPmit
r96, NADHcyt,trans NADHcyt ↔ NADPHcyt
Synthesis of macromolecules and biomass
r97, μ 0.552 proteins + 0.263 carbohydrates + 0.131 lipids +
0.023 DNA + 0.031 RNA→ biomass
Proteins [1 g] = 955.79 Aspcyt + 1344.29 Alacyt + 543.16 Glncyt + + 817.99
Glucyt + 1024.72 Argcyt + 362.10 Asncyt + 19.61 Cyscyt + 913.16 Glycyt + 271.58
Hiscyt + 240.54 Ilecyt + 588.41 Leucyt + 724.21 Lyscyt + 191.97 Valcyt + 114.57
Metcyt + 201.91 Phecyt + 205.97 Procyt + 247.44 Sercyt + 202.07 Thrcyt + 21.17
Trpcyt + 61.87 Tyrcyt + 24046.3 ATPcyt
Lipids [1 g] = 181 CH + 661.4 PC + 250.3 PE + 90.9 PI + 24.9 PS + 12.6 PGL +
81.4 SM + 26.8 DPG
DNA [1 g] = 3009 R5Pcyt + 3912 Aspcyt + 5717 Glncyt + -2106 NADHcyt + 1505
Glycyt + 22569 ATPcyt + 903 NADHmit + -2407 Malcyt + 903 NADPHcyt + -5717
Glucyt + 5417 MTHFcyt + -5417 THFcyt
RNA [1 g] = 3020 R5Pcyt + 3606 Aspcyt + 6316 Glncyt + 293 O2,cyt + -2435
NADHcyt + 1477 Glycyt + 22614 ATPcyt + 586 NADHmit + -2069 Malcyt + -2954
NADPHcyt + -6316 Glucyt + 4431 MTHFcyt + -4431 THFcyt
Carbohydrates [1 g] = 6172.8 G6Pcyt + 21605 ATPcyt
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ditions, upper bounds of unknown reaction rates were set
to 10000 μmol/gDW/h. The optimization problems stud-
ied by FVA then read
rminu;i ¼ minr ru;i OR rmaxu;i ¼ maxr ru;i
s:t:
Nuru ¼ −Nkrk
0≤ri≤10000 ∀i reaction i irreversible
−10000≤ri≤10000 ∀i reaction i reversible
ð4Þ
As a result from the 2∗u optimizations (u = number of
unknown fluxes), we obtained the physiologically feasible
flux range for the unknown reactions. Moreover, if the
computed minimal and maximal rate of a reaction coin-
cide (ru,i
min = ru,i
max), the reaction rate follows to be uniquely
determined. Note that FVA as described above does not
make any assumption about biological objectives in con-
trast to flux balance analysis [59]. The objective function
in equation (4) only serves as a tool to identify the feasible
flux ranges. This approach has also been used to estimate
flux distributions in CHO cells and was introduced under
the term flux-spectrum [60].
We define two scenarios where we consider different
sets of constraints. In scenario 1, we applied the measured
rate values plus/minus their corresponding standard devi-
ations as upper/lower boundaries for the corresponding
rates. In case that the lower boundary of an uptake rate
becomes negative, we set it to zero. Rates that were mea-
sured not to be active (e.g. uric acid excretion and alanine
uptake) were also fixed to zero. No further constraints
were used so that the results obtained with this scenario
are robust against measurement errors and assumptions
on reaction activities. However, since the system is under-
determined with these constraints, only flux ranges can be
calculated via FVA.
In scenario 2, we set the measured uptake/excretion
rates as fixed constraints. To resolve the anaplerotic fluxes
and since the corresponding flux range contains zero (see
Results), we assumed the pyruvate-carboxylase (r46) to be
inactive. This assumption is biologically reasonable as it is
often described and assumed to be negligible in trans-
formed cell cultures (e.g. in [25,61]) and supported by our
enzyme measurements. With these constraints the net-
work is over-determined with two degrees of redundancy.
By applying MFA with a variance-weighted least squares
estimation [57], we can calculate a unique flux distribution.
To avoid a significant deviation of the estimated against
the measured growth rate, we set the measurement vari-
ance of the growth rate to 1 × 10-9 in scenario 2.
All computations presented in this study were performed
with our software CellNetAnalyzer, a MATLAB toolbox
with graphical user interface facilitating metabolic network
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magdeburg.mpg.de/projects/cna/cna.html, and the net-
work project files will be made available on this site
within CellNetAnalyzer’s model repository.Additional file
Additional file 1: Table S1. Amino acid composition of cell protein
from CR.pIX cells and other cell lines. Table S2. Calculated rate ranges
(scenario 1; by FVA) or rates (scenario 2; by MFA) for CR.pIX cells cultured
in stirred tank reactors. Table S3. Measured concentrations, standard
deviations of validated assays, and measurement devices.Competing interests
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